Wikipedia

User:HHA LTP/sandbox

< User:HHA LTP
David E. Olson
NationalityAmerican
Alma materUnion College, Stanford University, Broad Institute of MIT and Harvard
Occupation(s)Chemical Neuroscientist, Professor, Entrepreneur
Employer(s)University of California, Davis; Delix Therapeutics
Known forDiscovery of neuroplasticity promoting effects of psychedelics
WebsiteOlsonlab.org

David E. Olson, PhD is an American chemist and neuroscientist. He is an associate professor of chemistry, biochemistry and molecular medicine at the University of California, Davis.[1]

Olson is best known for his work investigating neuroplasticity promoting compounds, especially the potential of psychedelic drugs, including ketamine and serotonergic psychedelics, to alter brain structure and function. Olson is able to separate the hallucinogenic effects of psychedelics from the rapid and sustained changes in the neuronal structure and function. Olson also coined a term to refer to small molecules that are fast acting, durable neuroplasticity promoting compounds: psychoplastogens. Psychoplastogens are being developed to treat a wide variety of neuropsychiatric and neurodegenerative diseases, including depression, PTSD, and substance use disorders, among many others.[2][3]

Early life

edit

Olson received his B.S. summa cum laude from Union College in 2006[4] with a major in chemistry and a minor in biology.

He then worked briefly at Albany Molecular Research Inc. before completing a Ph.D. in chemistry at Stanford University[4] in 2011, where he worked in the laboratory of Justin Du Bois, developing a variety of methods for synthesizing nitrogen-containing compounds.[5]

Olson undertook postdoctoral research in neuroscience at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard where he focused on the therapeutic potential of HDAC inhibitors.[6]

Career

edit

In 2015 Olson started his independent career at the University of California, Davis with a joint appointment in the Department of Chemistry (College of Letters and Science) and the Department of Biochemistry and Molecular Medicine (School of Medicine).[7] He is also an affiliate member of the Center for Neuroscience and the UC Davis Memory and Plasticity Program.[8] In 2021, Olson was promoted to associate professor with tenure.

In 2019, Olson co-founded Delix Therapeutics—a biotech company focused on developing novel neuroplasticity-promoting therapeutics for central nervous system diseases (CNS).[9] Olson served as the company's Chief Scientific Officer until 2021, when he transitioned to the role of Chief Innovation Officer and Head of the Scientific Advisory Board.[10]

In 2021, Olson was awarded the UC Davis Innovator of the Year Award in recognition of his research leading to the founding of Delix Therapeutics.[11]

Also in 2021, Olson’s company secured a $70 million Series A financing round to continue work on neuroplasticity therapeutics[12], and they began working with the National Institute on Drug Abuse (NIDA) to screen psychoplastogens as a potential treatment for a range of substance use disorders.[13]

Other activities

edit

Currently, he serves on the editorial advisory boards of the journals ACS Chemical Neuroscience[14] and ACS Pharmacology & Translational Science.[15]

Published works

edit

Olson has published numerous scientific publications.[16] Several of his key contributions to the field are cited below:

  • Dong, C.; Ly, C.; Dunlap, L. E.; Vargas, M. V.; Sun, J.; Hwang, I.-W.; Azinfar, A.; Oh, W. C.; Wetsel, W. C.; Olson, D. E.; Tian, L. Psychedelic-Inspired Drug Discovery Using an Engineered Biosensor. Cell, 2021, 184, 2779–2792.
  • Cameron, L. P.; Tombari, R. J.; Lu, J.; Pell, A. J.; Hurley, Z. Q.; Ehinger, Y.; Vargas, M. V.; McCarroll, M. N.; Taylor, J. C.; Myers-Turnbull, D.; Liu, T.; Yaghoobi, B.; Laskowski, L. J.; Anderson, E. I.; Zhang, G.; Viswanathan, J.; Brown, B. M.; Tjia, M.; Dunlap, L. E.; Rabow, Z. T.; Fiehn, O.; Wulff, H.; McCorvy, J. D.; Lein, P. J.; Kokel, D.; Ron, D.; Peters, J.; Zuo, Y.; Olson, D. E. A Non-Hallucinogenic Psychedelic Analogue with Therapeutic Potential. Nature, 2021, 589, 474–479.
  • Dunlap, L. E.; Azinfar, A.; Ly, C.; Cameron, L. P.; Viswanathan, J.; Tombari, R. J.; Myers-Turnbull, D.; Taylor, J. C.; Grodzki, A. C.; Lein, P. J.; Kokel, D.; Olson, D. E. Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogs Through Structure-Activity Relationship Studies. J. Med. Chem., 2020, 63, 1142–1155.
  • Cameron, L. P.; Benson, C. J.; DeFelice, B. C.; Fiehn, O.; Olson, D. E. Chronic, Intermittent Microdoses of the Psychedelic N,N‐Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents. ACS Chem. Neurosci., 2019, 10, 3261−3270.
  • Ly, C.; Greb, A. C.; Cameron, L. P.; Wong, J.; Barragan, E.; Wilson, P.; Burbach, K. F.; Dunlap, L. E.; Soltanzadeh Zarandi, S.; Sood, A.; Duim, W. C.; Paddy, M. R.; Dennis, M.; McAllister, A. K.; Ori-McKenney, K. M.; Gray, J. A.; Olson, D. E. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018, 23, 3170–3182.

Awards and honors

edit
Year Award and honors
2021 Sigma Xi Young Investigator Award[17]
2021 UC Davis Chancellor's Innovation Awards – Innovator of the Year[11]
2021 Camille Dreyfus Teacher-Scholar[18]
2021 Listed as one of the 100 Most Influential People in Psychedelics by Psychedelic Invest[19]
2021 UC Davis Graduate Studies Distinguished Graduate and Postdoctoral Mentoring Award[20]
2021 Lux Lectureship at The University of California Chemical Symposium[21]
2021 Dr. Mohsen Najafi Research Award in Medicinal Chemistry[22]
2020 Life Young Investigator Award[23]
2020 Jordi Folch-Pi Award from the American Society for Neurochemistry[24]
2020 ACS Division of Organic Chemistry Academic Young Investigator[25]
2019 Phi Beta Kappa Northern California Association Excellence in Teaching Award[26]
2018 Hellman Fellow[27]
2018 University Honors Program Faculty Award for Outstanding Mentorship[4]
2016 Dean's Award for Excellence in Mentoring at Early to Mid-Career Level[4]
2009 Eli Lilly Fellowship[28]
2008 John Stauffer Memorial Fellowship[28]
2007 Eli Lilly Fellowship[28]
2006 Phi Beta Kappa[29]
2006 George H. Catlin Prize[29]
2006 Robert M. Fuller Prize[29]
2005 Barry M. Goldwater Scholarship[27]

References

edit
  1. ^ Marrush, Najwa (2017-07-27). "David E. Olson, Ph.D." UC Davis Center for Neuroscience. Retrieved 2022-08-18.
  2. ^ Yakowicz, Will. "Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip". Forbes. Retrieved 2022-08-18.
  3. ^ Smith, Dana G. (2022-07-15). "Opinion | Taking the Magic Out of Magic Mushrooms". The New York Times. ISSN 0362-4331. Retrieved 2022-08-18.
  4. ^ a b c d Marrush, Najwa (2017-07-27). "David E. Olson, Ph.D." UC Davis Center for Neuroscience. Retrieved 2022-06-09.
  5. ^ Olson, David E.; Maruniak, Autumn; Malhotra, Sushant; Trost, Barry M.; Du Bois, J. (2011-07-01). "Synthesis and Reactivity of Unique Heterocyclic Structures en Route to Substituted Diamines". Organic Letters. 13 (13): 3336–3339. doi:10.1021/ol2010769. ISSN 1523-7060. PMC 3123413. PMID 21618989.
  6. ^ Olson, David E.; Sleiman, Sama F.; Bourassa, Megan W.; Wagner, Florence F.; Gale, Jennifer P.; Zhang, Yan-Ling; Ratan, Rajiv R.; Holson, Edward B. (2015-04-23). "Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via a histone deacetylase-independent catalase-like mechanism". Chemistry & Biology. 22 (4): 439–445. doi:10.1016/j.chembiol.2015.03.014. ISSN 1879-1301. PMC 4562013. PMID 25892200.
  7. ^ Marrush, Najwa (2017-07-27). "David E. Olson, Ph.D." UC Davis Center for Neuroscience. Retrieved 2022-08-18.
  8. ^ "Leadership". UC DAVIS MEMORY AND PLASTICITY PROGRAM. Retrieved 2021-08-27.
  9. ^ Yakowicz, Will. "Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip". Forbes. Retrieved 2022-06-09.
  10. ^ LaHucik, Kyle (2021-09-27). "Delix raises $70M to test psychedelic analogs for treating brain disorders in clinical trials next year". Fierce Biotech. Retrieved 2022-08-18.
  11. ^ a b Fell, Andy (2021-06-24). "Innovators' Achievements Honored With 2021 Chancellor's Innovation Awards". UC Davis. Retrieved 2022-06-09.
  12. ^ Salarizadeh, Cynthia; Salarizadeh, Cynthia (2022-03-11). "How Capital Markets Are Fueling Psychedelic Medicine Growth". Rolling Stone. Retrieved 2022-08-18.
  13. ^ Yakowicz, Will. "U.S. Government Will Test Ibogaine Derivative As An Addiction Treatment". Forbes. Retrieved 2022-08-18.
  14. ^ "Editorial Board". pubs.acs.org. Retrieved 2022-06-15.
  15. ^ "Editorial Board". pubs.acs.org. Retrieved 2022-06-15.
  16. ^ "My Bibliography - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2022-06-09.
  17. ^ "David Olson". www.sigmaxi.org. Retrieved 2022-06-09.
  18. ^ Oskin, Becky (2021-05-07). "David Olson Wins $100K Camille Dreyfus Teacher-Scholar Award". UC Davis College of Letters and Science. Retrieved 2022-06-09.
  19. ^ "100 Most Influential People in Psychedelics". Psychedelic Invest. Retrieved 2022-06-09.
  20. ^ Anonymous (2021-05-12). "Announcing the 2021 Distinguished Graduate and Postdoctoral Scholar Mentoring Award Recipients". UC Davis Graduate Studies. Retrieved 2022-06-09.
  21. ^ "2021 (Virtual)". UC Chemical Symposium. Retrieved 2022-06-09.
  22. ^ "Dr. David Olson was awarded Dr. Mohsen Najafi Research Award | UC Davis Alzheimer's Disease Center". health.ucdavis.edu. Retrieved 2022-06-09.
  23. ^ "Life". www.mdpi.com. Retrieved 2022-06-09.
  24. ^ "American Society for Neurochemistry - Recipients of the Jordi Folch-Pi Award". www.asneurochem.org. Retrieved 2022-06-09.
  25. ^ "Academic Young Investigator's Symposium (YAS) - ACS Division of Organic Chemistry". 2016-11-22. Retrieved 2022-06-09.
  26. ^ "Phi Beta Kappa Northern California Association - Teaching-past". pbknca.com. Retrieved 2022-06-09.
  27. ^ a b deolson (2017-06-13). "David E. Olson". Chemistry. Retrieved 2022-06-09.
  28. ^ a b c "David E. Olson, Ph.D. - Neuroscience - UC Davis Health". physicians.ucdavis.edu. Retrieved 2022-06-09.
  29. ^ a b c "Prize Day recipients announced". Union College News Archives. 2006-05-10. Retrieved 2022-06-09.

Category:Neuroscientists Category:American chemists

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:HHA_LTP/sandbox&oldid=1107565531"